(Total Views: 857)
Posted On: 07/30/2020 5:35:57 PM
Post# of 148908
my email to Nader after the CC
"Overall I think the call went well minus the ridiculous Q&A session. Maybe when topline results are reported we can get pre-screened questions that are insightful and add color to the call.
Keep up the good work. Can't wait to have Leronlimab in my arsenal when I treat patients.
***What has not been asked or emphasized is the mechanism of action (MOA) that set Leronlimab apart from the other 2000 candidates. THIS IS IMPORTANT. I believe as a physician scientist that the MOA is incredibly UNIVERSAL and can be implicated in ALL respiratory viral illnesses. Just imagine that instead of the standard Azithromycin/Prednisone script given to COPD exacerbations, a leronlimab shot would be the new standard of care (SOC).
I totally understand that we need to get a victory and approval before all the other implications of this drug but I hope we "don't miss seeing the forest for the trees." Basically to reiterate, our drug is not unique to COVID-19 it is the MOA, that is unique to the drug and gives us victory! THE MOA IS UNIVERSAL TO INFLAMMATORY conditions (NASH, MS, spondyloarthropathies etc...). Coronavirus is a zoonotic virus that causes the common cold (2nd most common) but this drug could be used in basically ANY AND ALL VIRAL DISEASES, BECAUSE WE REPROGRAM THE IMMUNE SYSTEM IN OUR FAVOR. This is why our drug is worth 1000x any specific MAB to COVID (ie REGN) or antiviral (GILD).
PLEASE help the general investor and medical community realize what we have and our potential. It's mind blowing to put it lightly."
"Overall I think the call went well minus the ridiculous Q&A session. Maybe when topline results are reported we can get pre-screened questions that are insightful and add color to the call.
Keep up the good work. Can't wait to have Leronlimab in my arsenal when I treat patients.
***What has not been asked or emphasized is the mechanism of action (MOA) that set Leronlimab apart from the other 2000 candidates. THIS IS IMPORTANT. I believe as a physician scientist that the MOA is incredibly UNIVERSAL and can be implicated in ALL respiratory viral illnesses. Just imagine that instead of the standard Azithromycin/Prednisone script given to COPD exacerbations, a leronlimab shot would be the new standard of care (SOC).
I totally understand that we need to get a victory and approval before all the other implications of this drug but I hope we "don't miss seeing the forest for the trees." Basically to reiterate, our drug is not unique to COVID-19 it is the MOA, that is unique to the drug and gives us victory! THE MOA IS UNIVERSAL TO INFLAMMATORY conditions (NASH, MS, spondyloarthropathies etc...). Coronavirus is a zoonotic virus that causes the common cold (2nd most common) but this drug could be used in basically ANY AND ALL VIRAL DISEASES, BECAUSE WE REPROGRAM THE IMMUNE SYSTEM IN OUR FAVOR. This is why our drug is worth 1000x any specific MAB to COVID (ie REGN) or antiviral (GILD).
PLEASE help the general investor and medical community realize what we have and our potential. It's mind blowing to put it lightly."
(11)
(0)Scroll down for more posts ▼
